Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05582876 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer

Study acronym: PROSPETMR2021
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 8, 2025 (before its estimated January 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Apr 30, 2024 to Jan 31, 2026
    • Study completion date: Nov 30, 2024 to Mar 31, 2026
    • Start date: Dec 12, 2022 to Jan 10, 2023
    v3
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 7
    • Start date changed from estimate of Dec 1, 2022 to Dec 12, 2022
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of multicentre phase 3 trial is evidence diagnostic value of 68Ga-PSMA-11 (in PET / CT and PET / MR techniques) in patients with high-risk and intermediate prostate cancer before radical treatment and in diagnosed patients biochemical recurrence after radical treatment
Trial Details
NCT Number NCT05582876
Lead Sponsor Medical University of Bialystok
Collaborators: Medical Research Agency, Poland
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 366 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov